Cyclessa

Cyclessa is a brand name of desogestrel/ethinyl estradiol, approved by the FDA in the following formulation(s):

CYCLESSA (desogestrel; ethinyl estradiol - tablet; oral-28)

• 
  Manufacturer: ORGANON USA INC
  
  Approval date: December 20, 2000
  
  Strength(s): 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG ^[RLD][AB]

Has a generic version of Cyclessa been approved?

Yes. The following products are equivalent to Cyclessa:

DESOGESTREL AND ETHINYL ESTRADIOL (desogestrel; ethinyl estradiol tablet; oral-28)

• 
  Manufacturer: WATSON LABS
  
  Approval date: January 24, 2006
  
  Strength(s): 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG ^[AB]

VELIVET (desogestrel; ethinyl estradiol tablet; oral-28)

• 
  Manufacturer: DURAMED PHARMS BARR
  
  Approval date: February 24, 2004
  
  Strength(s): 0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cyclessa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Cyclessa.

See also...

• Cyclessa Consumer Information (Cerner Multum)
• Desogestrel/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and desogestrel Consumer Information (Cerner Multum)

Asmanex Twisthaler

Asmanex Twisthaler is a brand name of mometasone, approved by the FDA in the following formulation(s):

ASMANEX TWISTHALER (mometasone furoate - powder; inhalation)

• 
  Manufacturer: SCHERING
  
  Approval date: March 30, 2005
  
  Strength(s): 0.22MG/INH ^[RLD]


• 
  Manufacturer: SCHERING
  
  Approval date: February 1, 2008
  
  Strength(s): 0.11MG/INH
  

Has a generic version of Asmanex Twisthaler been approved?

No. There is currently no therapeutically equivalent version of Asmanex Twisthaler available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Asmanex Twisthaler. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Inhalation device for powdered medicaments
  Patent 5,394,868
  Issued: March 7, 1995
  Inventor(s): Ambrosio; Thomas J. & Manthena; Srinivas & Sochon; Henry R.
  Assignee(s): Schering Corporation
  A powder dispenser 10 includes a powder housing 28 for holding a supply of powdered material to be dispensed, the powder housing including a first conduit 32 extending there through in displaced relation to the powdered material; a metering plate 16 having only a single receptacle area 24 for holding a metered amount of the powdered material above a gas-permeable powder retainer 26 mounted at the metering plate, and being positioned below the powdered material, and the metering plate and the powder housing being rotatable with respect to each other so that the receptacle area is adapted to be in selective communication with the supply of powdered material or the first conduit; a base housing 48 being mounted below the metering plate and including a second conduit 52 in alignment with the first conduit at least concurrently with alignment of the receptacle area and the first conduit; a spring 62 for biasing the base housing and the powder housing toward each other; a mouthpiece 92 for enabling inhalation of the metered amount of powdered material from the receptacle area in the metering plate through the first conduit in the container, the mouthpiece being in fluid communication with the first conduit.
  
  Patent expiration dates:
  
  
  • June 25, 2012
    
    ✓ 
    Drug product
  
  
  
  • December 25, 2012
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Inhaler for powdered medications having spiral deagglomeration chamber
  Patent 5,687,710
  Issued: November 18, 1997
  Inventor(s): Ambrosio; Thomas J. & Bilanin; Alan J. & Kaufman; Andrew E. & Kenyon; David J. & Manthena; Srinivas & Yang; Tsong-Toh
  Assignee(s): Schering Corporation
  A powder dispenser includes a powder housing for holding a supply of powdered material to be dispensed, the powder housing including an inhalation conduit provided displaced relation to the powdered material supply; a metering plate including a metered dose hole for holding a metered amount of the powdered material, and positioned below the powdered material supply, the metering plate and the powder housing being relatively rotatable with respect to each other about a common central axis; a counter providing a visual count of the number of doses of the powdered material that have been dispensed or remain to be dispensed in response to the relative rotation, the counter including counter rings providing the visual count, the counter rings being rotatable about the common central axis and having indicia thereon which display the visual count, and an actuating mechanism rotatable about the central axis for incrementally rotating the counter rings in response to the relative rotation; a nozzle for breaking up agglomerates of powdered material from the inhalation conduit to form micronized powdered material, the nozzle including a cavity for changing the direction of flow of the powder from the direction of the inhalation conduit to a second different direction, and a curved wall for substantially continuously changing the direction of flow of the powder in a spiral manner in the second direction in the cavity; and a closure cap covering the powder housing and priming the powder dispenser for use automatically upon removal thereof.
  
  Patent expiration dates:
  
  
  • November 18, 2014
    
    ✓ 
    Drug product
  
  
  
  • May 18, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Inhaler for powdered medications
  Patent 5,829,434
  Issued: November 3, 1998
  Inventor(s): Ambrosio; Thomas J. & Ashley; Charles R. & Bilanin; Alan J. & Huck; Charles M. & Kaufman; Andrew E. & Kenyon; David J. & Manthena; Srinivas & Sochon; Henry R. & Wilkinson; Ken & Yang; Tsong-Toh
  Assignee(s): Schering Corporation
  A powder inhaler comprising: a powder housing for holding a supply of powdered material to be dispensed and a metering plate for holding a metered amount of said powdered material, the metering plate being alternately positionable below said supply of powdered material or within an inhalation conduit, by means of a bi-directional, angle-limited relative rotation about a common central axis; a counter for providing a visual count of the number of doses of said powdered material that have been dispensed or remain to be dispensed in response to the relative rotation, the counter including: a continuous counter ring and a coaxially mounted intermittent counter ring, both rings being mounted on a base in surrounding relation to a retaining post, being rotatable about the common central axis and having counting indicia thereon for displaying said visual count; and a display means through which at least one of the counting indicia is displayed to indicate a count corresponding to a number of doses of powdered material that have been dispensed or remain to be dispensed.
  
  Patent expiration dates:
  
  
  • November 3, 2015
    
    ✓ 
    Drug product
  
  
  
  • May 3, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of mometasone furoate for treating lower airway passage and lung diseases
  Patent 5,889,015
  Issued: March 30, 1999
  Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,057,307
  Issued: May 2, 2000
  Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
    ✓ 
    Drug product
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Powdered medication inhaler
  Patent 6,240,918
  Issued: June 5, 2001
  Inventor(s): Ambrosio; Thomas J. & Benson, Jr.; Warren A. & Dao; Kim C. & Kenyon; David J. & Kreiseder; Walter J. & Schonebaum; Theodore J. & Vogel; Allen J. & Walker; Louis B. & Yang; Tsong-Toh
  Assignee(s): Schering Corporation
  A powder dispenser includes a reservoir body including a supply of powder and an inhalation conduit; a driving body for rotating the reservoir body and including upper recesses and two spring fingers in lower driving recesses thereof; a rotatable metering plate for carrying a metered amount of powder from the supply to the inhalation conduit, and having an underside with ribs; a gas permeable retainer welded to the ribs; a spring biasing the metering plate toward the reservoir body; a nozzle having spiked ribs welded in the upper recesses of the driving body and including a chimney with vertical flutes; an adapter non-rotatably mounted with respect to the metering plate and including two locking recesses for receiving the spring fingers for locking engagement and two helical cam tracks with a square cross-section; a closure cap covering the driving body and including priming ribs biasing the spring fingers out of the locking recesses and engaging with the locking recesses to rotate the driving body, and two cams riding within the cam tracks; a base non-rotatably connected with the metering plate; and a counter rotatably mounted on the base and including rotatable counter rings providing a visual count of the number of doses of powder to be dispensed, and a pawl assembly engaging with gear teeth of the counter rings for rotating the same, the pawl assembly including an outer wall, a pawl and a pawl spring integrally molded as a single piece.
  
  Patent expiration dates:
  
  
  • February 20, 2017
    
    ✓ 
    Drug product
  
  
  
  • August 20, 2017
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,365,581
  Issued: April 2, 2002
  Inventor(s): Joel A.; Sequeira & Francis M.; Cuss & Keith B.; Nolop & Imtiaz A.; Chaudry & Nagamani; Nagabhushan & James E.; Patrick & Mitchell; Cayen
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Preparation of powder agglomerates
  Patent 6,503,537
  Issued: January 7, 2003
  Inventor(s): Tsong-Toh; Yang
  Assignee(s): Schering Corporation
  The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
  
  Patent expiration dates:
  
  
  • March 17, 2018
    
    ✓ 
    Drug product
  
  
  
  • September 17, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,677,322
  Issued: January 13, 2004
  Inventor(s): Joel A.; Sequeira & Francis M.; Cuss & Keith B.; Nolop & Imtiaz A.; Chaudry & Nagamani; Nagabhushan & James E.; Patrick & Mitchell; Cayen
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Use of mometasone furoate for treating airway passage and lung diseases
  Patent 6,949,532
  Issued: September 27, 2005
  Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
  Assignee(s): Schering Corporation
  The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
  
  Patent expiration dates:
  
  
  • January 27, 2014
    
    ✓ 
    Patent use: TREATMENT OF ASTHMA
  
  
  
  • July 27, 2014
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 1, 2011 - NEW PATIENT POPULATION
  
  

See also...

• Asmanex Consumer Information (Drugs.com)
• Asmanex Twisthaler Powder Consumer Information (Wolters Kluwer)
• Asmanex Twisthaler 120 Dose Consumer Information (Cerner Multum)
• Asmanex Twisthaler 14 Dose Consumer Information (Cerner Multum)
• Asmanex Twisthaler 30 Dose Consumer Information (Cerner Multum)
• Asmanex Twisthaler 60 Dose Consumer Information (Cerner Multum)
• Asmanex Twisthaler 7 Dose Consumer Information (Cerner Multum)
• Asmanex Twist Advanced Consumer Information (Micromedex)
• Asmanex Twisthaler Advanced Consumer Information (Micromedex)
• Asmanex AHFS DI Monographs (ASHP)
• Mometasone Powder Consumer Information (Wolters Kluwer)
• Mometasone inhalation Consumer Information (Cerner Multum)
• Azmax Twisthaler Advanced Consumer Information (Micromedex)
• Mometasone Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)
• Mometasone Furoate AHFS DI Monographs (ASHP)

Histacetyl

Histacetyl may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Histacetyl

Dimetridazole

Dimetridazole is reported as an ingredient of Histacetyl in the following countries:

• France

Spiramycin

Spiramycin is reported as an ingredient of Histacetyl in the following countries:

• France

International Drug Name Search

Vanapen

Vanapen may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Vanapen

Benzylpenicillin

Benzylpenicillin procaine (a derivative of Benzylpenicillin) is reported as an ingredient of Vanapen in the following countries:

• Austria

International Drug Name Search

Sucralfate

In some countries, this medicine may only be approved for veterinary use.

In the US, Sucralfate (sucralfate systemic) is a member of the drug class miscellaneous GI agents and is used to treat Duodenal Ulcer, Duodenal Ulcer Prophylaxis, GERD, Hyperphosphatemia of Renal Failure, Stomach Ulcer, Stomatitis and Stress Ulcer Prophylaxis.

US matches:

• Sucralfate


• Sucralfate Suspension

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

A02BX02

CAS registry number (Chemical Abstracts Service)

0054182-58-0

Chemical Formula

C12-H54-Al16-O75-S8

Molecular Weight

974

Therapeutic Categories

Treatment of peptic ulcer

Protectant of gastrointestinal mucosa

Chemical Name

Sucrose hydrogen sulfate basic aluminium salt

Foreign Names

• Sucralfatum (Latin)
• Sucralfat (German)
• Sucralfate (French)
• Sucralfato (Spanish)

Generic Names

• Sucralfate (OS: BAN, USAN, JAN, DCF)
• Sucralfato (OS: DCIT)
• CGA-6J (IS)
• OS 202 (IS)
• Sucralfate (PH: USP 32, JP XIV)

Brand Names

• Alfate
  Stadmed, India



• Alsucral
  Orion, Finland; Orion, Singapore



• Altsamin
  Taiyo Pharmaceutical, Japan



• Alusulin
  Teva, Hungary



• Andapsin
  Orion, Sweden



• Antepsin
  Baldacci, Italy; Bilim, Turkey; Boehringer Ingelheim, Argentina; Chugai, United Kingdom; Chugai, Ireland; Orion, Denmark; Orion, Finland; Orion, Iceland; Orion, Norway



• Antepsin (veterinary use)
  Chugai, United Kingdom



• Apo-Sucralfate
  Apotex, Canada; Apotex, Hong Kong; Apotex, Singapore



• Bingast
  Nichi-Iko PharmaceuticalJMA, Japan



• Calfate
  Angelini, Portugal



• Carafate
  Aspen, Australia; Aspen, New Zealand; Axcan, United States



• Citogel
  Geymonat, Italy



• Crafilm
  Francia, Italy



• Dip
  Merck, Colombia; Merck, Ecuador; Merck, Venezuela



• Escudo
  Lampugnani, Italy



• Exinol
  Sankyo, Venezuela



• Gastalfet
  Beximco, Bangladesh



• Gastonic
  Nipa, Bangladesh



• Gastrofait
  E.I.P.I.C.O., Romania; Eipico, United Arab Emirates; Eipico, Bahrain; Eipico, Iraq; Eipico, Jordan; Eipico, Kuwait; Eipico, Lebanon; Eipico, Libya; Eipico, Oman; Eipico, Qatar; Eipico, Saudi Arabia; Eipico, Sudan; Eipico, Yemen



• Gastrogel
  Giuliani, Italy



• Inpepsa
  Fahrenheit, Indonesia



• Iselpin
  Wyeth, Philippines



• Keal
  EG Labo, Luxembourg



• Kéal
  EG Labo, France



• Ketodol (Sucralfate and Ketoprofen)
  Alfa Wassermann, Italy



• Medgel
  Medicraft, Myanmar



• Mulcatel
  Maver, Chile



• Musin
  Otto, Indonesia



• Muttermin
  Kyowa Yakuhin, Japan



• Neciblok
  Kalbe, Indonesia



• Netunal
  Merck, Argentina



• Nu-Sucralfate
  Nu-Pharm, Canada



• Ohnesmin
  Tsuruhara Seiyaku, Japan



• Peptonorm
  Uni-Pharma, Greece



• Propepsa
  Gracia Pharmindo, Indonesia



• Regel
  Solitaire, India



• Regel-SO (Sucralfate and Oxethazaine)
  Solitaire, India



• Ritaalumin
  Choseido Pharmaceutical, Japan



• Shualmin
  Sandoz, Japan



• Sucrabest
  Combustin, Germany; Hexal, Luxembourg



• Sucrahasan
  Hasan, Vietnam



• Sucral
  Ranbaxy, Thailand



• Sucralan
  Lannacher, Austria; Lannacher, Czech Republic; Lannacher, Romania



• Sucralfaat Katwijk
  Apotex Europe, Netherlands



• Sucralfaat Merck
  Merck Generics, Netherlands



• Sucralfaat PCH
  Pharmachemie, Netherlands



• Sucralfaat ratiopharm
  ratiopharm, Netherlands



• Sucralfaat Sandoz
  Sandoz, Netherlands



• Sucralfat Genericon
  Genericon, Austria



• Sucralfat
  Actavis, Georgia; Medica, Georgia



• Sucralfate RPG
  RPG, France



• Sucralfate Teva
  Teva Santé, France



• Sucralfate
  Eon, United States; Kyowa Yakuhin, Japan; Martec, United States; Pharmaceutical Associates, United States; ratiopharm, United States; Teva USA, United States; Towa Yakuhin, Japan; UDL, United States; Watson, United States



• Sucralfato ABC
  ABC, Italy



• Sucralfato Angenerico
  Angenerico, Italy



• Sucralfato BIG
  Benedetti, Italy



• Sucralfato Denver
  Denver, Argentina



• Sucralfato DOC
  DOC Generici, Italy



• Sucralfato Ecar
  Ecar, Colombia



• Sucralfato Generis
  Generis, Portugal



• Sucralfato Merck
  Merck Genéricos, Portugal; Merck Generics, Italy



• Sucralfato Pliva
  Pliva, Italy



• Sucralfato Teva
  Teva, Italy



• Sucralfato
  Synthesis, Colombia



• Sucralfat-ratiopharm
  Ratiopharm, Germany



• Sucralfin
  Sanofi-Aventis, Italy



• Sucralmax
  Quesada, Argentina



• Sucramal
  Menarini, United Arab Emirates; Menarini, Bahrain; Menarini, Costa Rica; Menarini, Cyprus; Menarini, Dominican Republic; Menarini, Egypt; Menarini, Guatemala; Menarini, Honduras; Menarini, Iraq; Menarini, Jordan; Menarini, Kuwait; Menarini, Lebanon; Menarini, Libya; Menarini, Morocco; Menarini, Nicaragua; Menarini, Panama; Menarini, Qatar; Menarini, Saudi Arabia; Menarini, Sudan; Menarini, El Salvador; Menarini, Syria; Menarini, Yemen; Sanofi-Aventis, Italy



• Sucramed
  S.Med, Austria



• Sucrase
  Zydus Cadila, India



• Sucrassyl
  Paill, Dominican Republic; Paill, Guatemala; Paill, Honduras; Paill, Nicaragua; Paill, Panama; Paill, El Salvador



• Sucrate
  Jida, China; Lisapharma, Italy; Lisapharma, Thailand



• Sucroril
  Sofar, Italy



• Sude
  Lisapharma, China



• Sugar
  Farma1, Italy



• Sugast
  SF, Italy



• Sulcran
  Silesia, Chile; Silesia, Peru



• Sulcrate
  Axcan, Canada



• Suril
  Ibirn, Italy



• Teigast
  Nichi-Iko PharmaceuticalJMA, Japan



• Tunalmin
  Maeda Yakuhin, Japan



• Ulcar
  Sanofi Aventis, Tunisia; Sanofi-Aventis, France



• Ulcefate
  Siam Bheasach, Thailand



• Ulcefix
  Pharmaghreb, Tunisia



• Ulcerlmin
  Chugai, Japan



• Ulcermin
  Bonafarma, Portugal



• Ulcertec
  DHA, Singapore



• Ulciram
  Vargas, Venezuela



• Ulcogant
  Dr. Fisher, Netherlands; Euro, Netherlands; Merck, Austria; Merck, Belgium; Merck, Switzerland; Merck, Costa Rica; Merck, Czech Republic; Merck, Germany; Merck, Dominican Republic; Merck, Guatemala; Merck, Honduras; Merck, Hungary; Merck, Luxembourg; Merck, Nicaragua; Merck, Netherlands; Merck, Panama; Merck, Peru; Merck, El Salvador



• Ulcon
  Farma, Venezuela



• Ulcrafate
  Polipharm, Thailand



• Ulcrast
  B&G, Italy



• Ulcyte
  Alphapharm, Australia



• Ulgastran
  Polfa Grodzisk, Poland



• Ulsafate
  Combiphar, Indonesia



• Ulsaheal
  Hikma, Oman



• Ulsanic
  Aspen Pharmacare Consumer, South Africa; Chugai, Hong Kong; Chugai, Thailand; Chugai, Taiwan; Teva, Israel



• Ulsec
  Asiatic Lab, Bangladesh



• Ulsicral
  Ikapharmindo, Indonesia



• Ulsidex
  Dexa Medica, Indonesia



• Unival
  Senosiain, Mexico



• Urbal
  Merck, Spain



• Venter
  Akrihin, Russian Federation; Krka, Czech Republic; Krka, Estonia; Krka, Georgia; Krka, Hungary; Krka, Lithuania; Krka, Latvia; Krka, Romania; Krka, Slovenia; Krka, Slovakia



• Yuwan
  Sawai Seiyaku, Japan

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Cytotec

In some countries, this medicine may only be approved for veterinary use.

In the US, Cytotec (misoprostol systemic) is a member of the drug class miscellaneous GI agents and is used to treat Abortion, Cervical Ripening, Duodenal Ulcer, Gynecological Conditions, Labor Induction, NSAID-Induced Ulcer Prophylaxis, Postpartum Bleeding and Stomach Ulcer.

US matches:

• Cytotec

UK matches:

• Cytotec Tablets (SPC)

Ingredient matches for Cytotec

Misoprostol

Misoprostol is reported as an ingredient of Cytotec in the following countries:

• Australia


• Bahrain


• Belgium


• Costa Rica


• Cyprus


• Denmark


• Egypt


• El Salvador


• Finland


• France


• Ghana


• Greece


• Guatemala


• Honduras


• Hong Kong


• Iceland


• Indonesia


• Ireland


• Israel


• Italy


• Japan


• Jordan


• Kenya


• Kuwait


• Luxembourg


• Malaysia


• Mexico


• Netherlands


• New Zealand


• Nigeria


• Norway


• Oman


• Panama


• Peru


• Poland


• Portugal


• Saudi Arabia


• Singapore


• South Africa


• Spain


• Sweden


• Switzerland


• Taiwan


• Thailand


• Turkey


• United Arab Emirates


• United Kingdom


• United States


• Venezuela

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.